This promotional material is intended for UK Healthcare Professionals experienced in the diagnosis and treatment of Chronic Migraine. BOTOX® (botulinum toxin type A) Prescribing Information and adverse event reporting information can be found below.
+30 YEARS' GLOBAL EXPERIENCE
ACROSS MULTIPLE INDICATIONS1-4
CHRONIC MIGRAINE
BOTOX® (botulinum toxin type A) is indicated for the prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).5
+30 YEARS' GLOBAL EXPERIENCE ACROSS MULTIPLE INDICATIONS1-4
CHRONIC MIGRAINE
BOTOX® (botulinum toxin type A) is indicated for the prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).5
Resources
BOTOX® (botulinum toxin type A) is indicated for the prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).5
Prescribing information and adverse event reporting can be found using the link above.
For healthcare professionals
BOTOX® Injection Site Anatomy Poster with Muscles and Nerves
This poster shows a summary of the PREEMPT treatment paradigm, a culmination of over 10 years’ experience of migraine research, optimised to help patients with chronic migraine maximise their likelihood of a beneficial effect.
To receive a copy of this poster, please submit your details on the Contact Us page and tick BOTOX® Injection Site Anatomy Poster with Muscles and Nerves.
BOTOX® dosage and administration guide
This guide provides a summary of the dosage and administration for BOTOX® and offers additional useful information on contraindications, injection sites, and recommended treatment intervals.
To receive a copy of this guide, please submit your details on the Contact Us page and tick BOTOX® dosage and administration guide.
Educational modules for healthcare professionals – E-learning
BOTOX® (Botulinum Toxin Type A) Chronic Migraine E-learning Module 1:
Understanding Chronic Migraine: Diagnosis and Management
This module, designed for UK healthcare professionals involved in the management of patients with CM includes; how to achieve a differential diagnosis of CM, the goals of CM treatment, a summary of the available treatment options and how to manage medication overuse headache.
BOTOX® (Botulinum Toxin Type A) Chronic Migraine E-learning Module 2:
Evidence Base for BOTOX® in Chronic Migraine
This module, designed for UK healthcare professionals involved in the management of patients with CM, provides an overview of the pivotal clinical trials and real-world evidence supporting the use of BOTOX® for the treatment of CM.
BOTOX® (Botulinum Toxin Type A) Chronic Migraine E-learning Module 3:
Reconstitution and Administration of BOTOX® for Chronic Migraine
This module, designed for UK healthcare professionals involved in the management of patients with CM includes; the reconstitution and administration of BOTOX® for patients with CM, the PREEMPT injection paradigm and protocols, along with considerations for before, during and after the BOTOX® injection procedure.
BOTOX® (Botulinum Toxin Type A) Chronic Migraine E-learning Module 4:
Improving Clinic Efficiency
This module, designed for UK healthcare professionals involved in the management of patients with CM, explores best practice tips and techniques regarding BOTOX® clinic setup and layout and provides guidance on how to improve clinic efficiency.
Resources for your patients
Patient Guide for the Treatment of Chronic Migraine with BOTOX®
To support your chronic migraine patients treated with BOTOX®, this guide provides information on how the treatment works, what to expect during and after treatment and potential side-effects.
The information in this guide does not replace the Patient Information Leaflet (PIL) that is enclosed with the prescribed medication.
To receive a copy of this guide, please submit your details on the Contact Us page and tick Chronic Migraine Patient Guide.
CM: chronic migraine; GIRFT: Getting It Right First Time.
References
- Allergan. Data on file. INT/0423/2016
- Aurora S K, Winner P et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
- Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
- AbbVie Data on file. Approval Dates for BOTOX® in UK. UK-BTX-230044. April 2023
- BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk.
Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use. The BOTOX® Summary of Product Characteristics can be found here
By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
Date of preparation: March 2025. UK-BCM-240129.
